Assess whether pediatric studies are necessary or waivable (d0ee28)

Situation

In a mid-size sponsor after a complete response letter, inspection-readiness findings at a CMO is the evidence after a CRL citing manufacturing, not efficacy. Pharmacovigilance medical reviewer has to pick Pediatric studies are necessary or Waivable for this Pharma & Life Sciences CMC and Development Pathways close using inspection-readiness findings at a CMO.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Pediatric studies are necessary / Waivable using inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Authorize Pediatric studies are necessary now; inspection-readiness findings at a CMO already has the discriminator after a CRL citing manufacturing, not efficacy.
• Keep Waivable in force until inspection-readiness findings at a CMO is completed after a CRL citing manufacturing, not efficacy for pharmacovigilance medical reviewer.
• Treat inspection-readiness findings at a CMO as Pediatric studies are necessary because both readings appear after a CRL citing manufacturing, not efficacy.
• Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page pediatric studies are necessary turns on in inspection-readiness findings at a CMO.

Analysis required

• Check whether inspection-readiness findings at a CMO supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a CRL citing manufacturing, not efficacy and write the one fact that would move pediatric studies are necessary for pharmacovigilance medical reviewer.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy). If inspection-readiness findings at a CMO cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy cannot support Pediatric studies are necessary versus Waivable on this Pharma & Life Sciences CMC and Development Pathways close, pharmacovigilance medical reviewer must state the unresolved clinical or safety evidence requirement explicitly.